Gum disease appears to disrupt brain activity, potentially increasing a person's risk of cognitive decline. People with gum ...

Patient enrollment is completed ahead of schedule for Contineum's Phase 2 clinical trial of PIPE-307, an oral remyelination ...

[3] Because of these barriers to injectable therapy and the increasing incidence of diabetes, more options for oral antidiabetic agents are warranted.

Neurosense entered a binding term sheet with a global pharmaceutical company to advance development and commercialization of ...

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and Wales. Final draft ...